


PhenoSENSE ENTRY

HIV DRUG RESISTANCE ASSAY




Formerly ViroLogic, Inc.
 Patrick Joseph, MD, Medical Director - 345 Oyster Point Blvd
 South San Francisco, CA 94080 - Tel: (800) 777-0177



Patient Initials:	DOB	Patient ID	Gender	Monogram Accession # 05-109825
Date Collected	Date Received	Date Reported	Mode	Report Status
Investigator			Specimen ID	
Comments:				

DRUG		PHENOSENSE™ SUSCEPTIBILITY				ASSESSMENT
Generic Name	Brand Name	Patient IC50 (µM)	Fold Change	Increasing Drug Susceptibility	Decreasing	Drug
Enfuvirtide	Fuzeon	0.081195	2.11			ENF Sensitive

Fold Change in IC50 of Patient Virus in relation to distribution of enfuvirtide-naive viral isolates*:



*The susceptibility cutoff for enfuvirtide is at the 99th percentile of the distribution of enfuvirtide phenotypes in a naive reference population. This reference population consisted of baseline isolates from the TORO1 and TORO2 clinical trials. Among these 220 baseline isolates a relatively broad range of enfuvirtide susceptibility was observed (geometric mean fold change = 1.54; 99th percentile: 0.42 - 6.48). The appropriate interpretation of phenotypic test results should take into consideration the natural variability in susceptibility of enfuvirtide-naive viruses and inherent assay variability.

Important Definitions

IC50: concentration of drug required to inhibit viral replication by 50%.

$$\text{Fold Change} = \frac{\text{IC50 patient}}{\text{IC50 reference}}$$

PhenoSense Entry is a proprietary, recombinant virus, single replication cycle assay which uses gp160 coding regions of HIV-1 from a patient blood sample to evaluate tropism and entry inhibitor susceptibility. The tropism assay meets the standards for performance characteristics and all other quality control and assurance requirements established by the Clinical Laboratory Improvement Act. The entry inhibitor susceptibility assay is performed as RUO (research use only). These results have been provided from confidential records and may not be disclosed to unauthorized persons without patient consent.